Treatment adherence in ophthalmology and astrophysics

Ocular Surface

Volumn 8, Issue 2, 2010, Pages 91-95

  Novack, Gary D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; AZITHROMYCIN; EYE DROPS; LATANOPROST; PILOCARPINE; PIRENZEPINE; PROSTAGLANDIN; TIMOLOL; TRAVOPROST; VALPROATE SEMISODIUM;

ARTICLE; GLAUCOMA; HEALTH CARE COST; INTRAOCULAR PRESSURE; MYOPIA; OPHTHALMOLOGY; PATIENT COMPLIANCE; PHARMACIST; PHYSICS; PILL; PRESCRIPTION;

EID: 77951754164     PISSN: 15420124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-0124(12)70073-3     Document Type: Article

References (44)

1. Hester J, Blumenthal G, Smith B, et al. 21st Century Astronomy. 2nd ed ed. New York, WW Norton & Co,2007, ed 2, p 536
2. Mansberger SL. Are you compliant with addressing glaucoma adherence? Am J Ophthalmol 2010;149:1-3
3. Glover FF. Dispenser for pharmaceuticals having patient compliance monitor apparatus. Alza Corporation. U.S.Patent [4,034,757]. 7-12-1977
4. Kass MA, Zimmerman T, Yablonski M, Becker B. Compliance to pilocarpine therapy (abstract). Invest Ophthalmol Vis Sci 1977; 108 (AR VO abstracts suppl)
5. Kass MA, Meltzer D, Gordon M. A miniature compliance monitor for ophthalmology. Arch Ophthalmol 1984;102:1550-1554
6. Kass MA, Meltzer DW, Gordon M, et al. Compliance with topical pilocarpine treatment. Am J Ophthalmol 1986;101:515-523
7. Norell SE. Improving medication compliance: a randomised clinical trial. BMJ 1979;2:1031-1033 (Pubitemid 10249394)
8. Norell SE, Granstrom PA. Self-medication with pilocarpine among outpatients in a glaucoma clinic. Br J Ophthalmol 1980;64:134-141
9. Tan DTH, Lam DS, Chua WH, et al. One-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. Ophthalmology 2005;112:84-91
10. Siatkowski RM, Cotter S, Miller JM, et al. Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: a 1-year, multicenter, double-masked, placebo-controlled parallel study. Arch Ophthalmol 2004;122:1667-1674 (Pubitemid 39473412)
11. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007;144:533-540
12. Hollo GA, Kothy PA, Geczy A, Vargha PA. Personality traits, depression, and objectively measured adherence to oncedaily prostaglandin analog medication in glaucoma. J Glaucoma 2009;18
13. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology 2009;116:191-199
14. Boden C, Sit A, Weinreb RN. Accuracy of an electronic monitoring and reminder device for use with travoprost eye drops. J Glaucoma 2006;15:30-34 (Pubitemid 43068417)
15. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin Pharmacol Ther 1989;46:163-168 (Pubitemid 19219952)
16. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000;3:417-426
17. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-461 (Pubitemid 34787476)
18. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336:1114-1117 (Pubitemid 351731741)
19. Wilensky J, Fiscella RG, Carlson AM, et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006;141:S28-S33 (Pubitemid 43028477)
20. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004;137:S3-S12
21. Schwartz GF, Platt R, Reardon G, Mychaskiw MA. Accounting for restart rates in evaluating persistence with ocular hypotensives. Ophthalmology 2007;114:648-652 (Pubitemid 46483699)
22. Platt R, Reardon G, Mozaffari E. Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size. Am J Ophthalmol 2004;137:S17-S23 (Pubitemid 38091631)
23. Blackwell B. Treatment adherence. Br J Psychiatry 1976;129:513-531
24. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497
25. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107:631-639 (Pubitemid 30191329)
26. Brown MM, Brown GC, Spaeth GL. Improper topical self-administration of ocular medication among patients with glaucoma. Can J Ophthalmol 1984;19:2-5 (Pubitemid 14159077)
27. Kass MA, Hodapp E, Gordon M, et al. Part I. Patient administration of eyedrops: interview. Ann Ophthalmol 1982;14:775-779 (Pubitemid 12047013)
28. Kass MA, Hodapp E, Gordon M, et al. Patient administration of eyedrops: observation. Part II. Ann Ophthalmol 1982;14:889-893 (Pubitemid 12024499)
29. Norell S. Medication behaviour. A study of outpatients treated with pilocarpine eye drops for primary open-angle glaucoma. Acta Ophthalmol Suppl (Copenh) 1980;143:1-28
30. Stone JL, Robin AL, Novack GD, et al. An objective evaluation of eye-drop instillation in glaucoma patients. Arch Ophthalmol 2009;127:732-736
31. Koldebarin R, Campbell RJ, Jin Y-P, et al. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol 2008;43:454-461
32. Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol 1986;101:524-530 (Pubitemid 16114196)
33. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology 2009;116:191-199
34. Nordmann JP, Baudouin C, Bron A, et al. Xal-Ease: impact of an ocular hypotensive delivery device on ease of eyedrop administration, patient compliance, and satisfaction. Eur J Ophthalmol 2009;19:949-956
35. Urquhart J. Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv Drug Deliv Rev 1998;33:207-219 (Pubitemid 28403623)
36. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336:1114-1117 (Pubitemid 351731741)
37. Vrijens B, Belmans A, Matthys K, et al. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf 2006;15:115-121 (Pubitemid 43316254)
38. Okeke CO, Quigley HA, Jampel HD, et al. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. Ophthalmology 2009;116:2286-2293
39. Chang JS, Jr., Lee DA, Petursson G, et al. The effect of a glaucoma medication reminder cap on patient compliance and intraocular pressure. J Ocular Pharmacology 1991;7:117-124
40. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol 1984;102:551-553
41. Vrijens B, Goetghebeur E, de Klerk E, et al. Modelling the association between adherence and viral load in HIV-infected patients. Stat Med 2005;24:2719-2731 (Pubitemid 41300806)
42. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30 (Pubitemid 30432540)
43. Hoer A, Seidlitz C, Gothe H, et al. Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence 2009;3:25-30
44. Novack GD. Ophthalmic drug delivery: Development and Regulatory Considerations. Clin Pharm Ther 2009;85:539-543